Dean Stull, Ph.D.
editBiography
Dean Stull holds a Ph.D. in physical organic chemistry and a master’s degree in organic chemistry from the University of Colorado and a bachelor‘s degree in chemistry from Colorado State University.
Dr. Stull has more than 30 years of experience in the pharmaceutical, food ingredient and dietary supplement industries. He has developed numerous ingredients for the pharmaceutical, food and nutraceutical markets; from products targeting cholesterol and vaccine adjuvants to natural antioxidants. He developed the first commercial technology for Paclitaxel (Taxol®) the API product which has become the largest cytotoxic anti-cancer drug in history.
Both scientist and businessman, Dr. Stull has been responsible for start ups, acquisitions, mergers, divestitures and numerous funding rounds, including two public stock offerings. He joined Efficas Inc. in March 2004 as chief scientific officer. Previously, Dr. Stull was president and founder of InB; Paxis Pharmaceuticals, Inc., and President of Hauser Pharmaceutical Services, Inc. He was also founder, CEO and Chairman of Hauser, Inc., a business which grew $125 million in revenue and 500 employees.